116424-69-2
116424-69-2 structure
- Name: fargesone A
- Chemical Name: (2S,3R,3aR,7S,7aS)-2-(1,3-benzodioxol-5-yl)-3a,4-dimethoxy-3-methyl-7-prop-2-enyl-2,3,7,7a-tetrahydro-1-benzofuran-6-one
- CAS Number: 116424-69-2
- Molecular Formula: C21H24O6
- Molecular Weight: 372.41
- Catalog: Natural product Lignans
- Create Date: 2016-01-05 22:55:23
- Modify Date: 2024-01-03 10:38:17
-
Fargesone A is a potent and selective FXR agonist. Fargesone A shows anti-inflammatory activity[1].
| Name | (2S,3R,3aR,7S,7aS)-2-(1,3-benzodioxol-5-yl)-3a,4-dimethoxy-3-methyl-7-prop-2-enyl-2,3,7,7a-tetrahydro-1-benzofuran-6-one |
|---|---|
| Synonyms |
(2S,3R,3aR,7S,7aS)-7-Allyl-2-(1,3-benzodioxol-5-yl)-3a,4-dimethoxy-3-methyl-3,3a,7,7a-tetrahydro-1-benzofuran-6(2H)-one
6(2H)-Benzofuranone, 2-(1,3-benzodioxol-5-yl)-3,3a,7,7a-tetrahydro-3a,4-dimethoxy-3-methyl-7-(2-propen-1-yl)-, (2S,3R,3aR,7S,7aS)- fargesone A |
| Description | Fargesone A is a potent and selective FXR agonist. Fargesone A shows anti-inflammatory activity[1]. |
|---|---|
| Related Catalog | |
| Target |
FXR[1] |
| In Vitro | Fargesone A (10 μM; 24 h) 以 FXR 依赖的方式减轻人肝脏 WRL68 细胞的肝细胞紊乱[1]。 Fargesone A 的激动作用是通过与 FXR 的直接相互作用实现的[1]。 |
| In Vivo | Fargesone A (3 and 30 mg/kg; i.p.; daily for 7 days) 可显著改善胆管结扎 (BDL) 诱导的慢性肝纤维化小鼠模型[1]。 Pharmacokinetics parameters of Fargesone A in mice t1/2 (h) Tmax (h) Cmax (ng/mL) AUC0-t (ng/mL*h) AUC0-inf (ng/mL*h) MRT0-inf (h) F (%) i.v. (5 mpk) 0.68±0.1 - 941±57 469±13 471±14 0.43±0.13 - p.o. (10 mpk) 0.33±0.04 0.25±0.00 104±16 101±32 102±32 0.58±0.07 10.8±3.2 Animal Model: C57BL/6 mice, bile duct ligation (BDL)-induced chronic liver fibrosis mouse model[1] Dosage: 3 and 30 mg/kg Administration: IP, once daily for 7 days Result: Resulted in a lower level of inflammatory infiltrates and a smaller amount of collagen deposition compared to the vehicle group. Reversed BDL-induced sharp increase in total bilirubin level in the serum. Significantly decreased liver mRNA expression of the inflammatory biomarkers interleukin (IL)-6, IL-1β, inducible nitric oxide synthase (iNOS), and prostaglandin-endoperoxide synthase 2 (COX2). Animal Model: C57BL6/J mice[1] Dosage: 5 or 10 mg/kg Administration: IV or PO (Pharmacokinetics Analysis) Result: Showed acceptable PK profiles in general. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 508.0±50.0 °C at 760 mmHg |
| Molecular Formula | C21H24O6 |
| Molecular Weight | 372.41 |
| Flash Point | 222.0±30.2 °C |
| Exact Mass | 372.157288 |
| PSA | 63.22000 |
| LogP | 3.76 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.576 |
| Hazard Codes | Xi |
|---|